Off-the-Shelf immune cells take on Hard-to-Treat cancers

NCT ID NCT06773091

Recruiting now Disease control Sponsor: Shanghai NK Cell Technology Co., LTD Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing NK042, a ready-made natural killer cell therapy made from healthy donors, in 76 people with advanced solid tumors that have not responded to standard treatments. Participants first receive chemotherapy to prepare their immune system, then an infusion of NK042 cells. The main goals are to check safety and find the right dose, while also looking for signs that the tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NK042 (natural killer cells from healthy donors)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 76 participants, so it is too soon to know if NK042 works. There may be side effects from the cells or the chemotherapy given beforehand.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Peking University Cancer Hospital
RECRUITING

Beijing, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.